Headquartered in Palo Alto, CA Fiscal year ends December NASDAQ: BBIO bridgebio.com
BridgeBio Pharma is a commercial-stage, multi-product biopharmaceutical company focused on developing and commercializing transformative medicines for genetic conditions. Its flagship product, Attruby (acoramidis), is a near-complete transthyretin stabilizer approved in the U.S., EU, Japan, Switzerland, Brazil, and the U.K. for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The company's pipeline spans multiple rare disease areas: BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), encaleret for autosomal dominant hypocalcemia type 1 (ADH1) and chronic hypoparathyroidism, and oral infigratinib for achondroplasia and hypochondroplasia. BridgeBio operates a decentralized hub-and-spoke model where autonomous teams focus on individual genetic conditions while a central hub provides clinical, regulatory, and commercial capabilities. The company also earns royalty revenue from BEYONTTRA (the branded name for acoramidis in the EU and Japan) through its partnership structure. BridgeBio trades on Nasdaq under the ticker BBIO. Updated
Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it was “Welcome back, my friends to the show that never ends.” On cue, the never-say-die…
BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with…
Pre-Market Stock Futures: Futures are trading lower after a big rate-cut rally on Wednesday was sideswiped by Oracle’s disappointing earnings after the bell yesterday. The Federal Reserve’s 25-basis-point rate cut, as expected,…
The latest Consumer Price Index (CPI) report has sparked optimism, revealing consumer prices rose 0.2% in July, meaning the index held steady from June at 2.7%. This was milder than anticipated, but…
A Fallen Giant Pfizer (NYSE:PFE | PFE Price Prediction) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted…
Wednesday's top analyst upgrades and downgrades included Accenture, Bridgebio Pharma, Chesapeake Energy, eBay, Hewlett Packard Enterprise, Huntsman, New York Community Bancorp, Nucor, Oracle, PBF Energy, Phillips 66, United States Steel and Valero…
Wednesday’s top analyst upgrades and downgrades included Adobe, Akamai Technologies, BridgeBio Pharma, Ciena, Eqonex, Hilton Worldwide, Paysafe, Riot Blockchain, Shopify, Tesla and Williams-Sonoma.
BridgeBio Pharma is a commercial-stage, multi-product biopharmaceutical company focused on developing and commercializing transformative medicines for genetic conditions.
24/7 Wall St.'s 12-month price target for BBIO is $125.68, rated Buy. The Wall Street consensus target is $109.10. BBIO price prediction →
